Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 5/2016

Open Access 01-05-2016 | Original Article

Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study

Authors: Sophie Nahon, Mansour Rastkhah, Meher Ben Abdelghani, Ravaka-Fatoma Soumoudronga, Isabelle Gasnereau, Jean-Luc Labourey

Published in: Supportive Care in Cancer | Issue 5/2016

Login to get access

Abstract

Purpose

Chemotherapy-induced neutropenia is a serious and potentially life-threatening consequence of cancer treatment. Prophylactic treatment with granulocyte-colony stimulating factor (G-CSF) decreases the incidence of febrile neutropenia, the rate of hospitalization, and the use of antibiotics in patients at risk. The aim of this study was to assess efficacy, safety, and use of Zarzio®—biosimilar of Neupogen® (G-CSF; filgrastim)—in prophylaxis of chemotherapy-induced neutropenia in current practice in cancer patients.

Methods

We conducted an observational, prospective, longitudinal, and multicentric study in France. The incidence of neutropenia was evaluated at each cycle of chemotherapy.

Results

One hundred eighty-four patients (women, 64.7 %; mean age, 61.7 years) with solid tumor (89.7 %; breast cancer, 50.5 %) or non-Hodgkin lymphoma (10.3 %) were included. The risk of febrile neutropenia based on chemotherapy regimen was >20 % for 32.1 % of patients. No case of febrile neutropenia was reported. Neutropenia was the cause of hospitalization and/or antibiotic therapy in 10 patients. The most frequent adverse events related to Zarzio® were pain, in particular bone pain. No serious adverse event related to Zarzio® was reported.

Conclusion

The results obtained in real-life conditions confirm that Zarzio® is efficient and well tolerated in cancer patients.
Literature
1.
Crawford J, Dale DC, Kuderer NM, Culakova E, Poniewierski MS, Wolff D, Lyman GH (2008) Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw 6:109–118PubMed
2.
Lyman GH, Delgado DJ (2003) Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 98:2402–2409CrossRefPubMed
3.
Lyman GH, Morrison VA, Dale DC, Crawford J, Delgado DJ, Fridman M (2003) Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin’s lymphoma receiving CHOP chemotherapy. Leuk Lymphoma 44:2069–2076CrossRefPubMed
4.
Timmer-Bonte JN, de Boo TM, Smit HJ, Biesma B, Wilschut FA, Cheragwandi SA, Termeer A, Hensing CA, Akkermans J, Adang EM, Bootsma GP, Tjan-Heijnen VC (2005) Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study. J Clin Oncol 23:7974–7984CrossRefPubMed
5.
Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL, Neumann TA, Schwartzberg LS (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23:1178–1184CrossRefPubMed
6.
Wolff D, Culakova E, Poniewierski MS, Lyman GH, Dale DC, Crawford J (2005) Predictors of chemotherapy-induced neutropenia and its complications: results from a prospective nationwide registry. J Support Oncol 3:24–25PubMed
7.
8.
Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730–751CrossRefPubMed
9.
10.
Padilla G, Ropka ME (2005) Quality of life and chemotherapy-induced neutropenia. Cancer Nurs 28:167–171CrossRefPubMed
11.
Wagner LI, Beaumont JL, Ding B, Malin J, Peterman A, Calhoun E, Cella D (2008) Measuring health-related quality of life and neutropenia-specific concerns among older adults undergoing chemotherapy: validation of the Functional Assessment of Cancer Therapy-Neutropenia (FACT-N). Support Care Cancer 16:47–56CrossRefPubMed
12.
Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, Kearney N, Lyman GH, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42:2433–2453CrossRefPubMed
13.
Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8–32CrossRefPubMed
14.
Lyman GH, Kuderer NM (2010) Prevention and treatment of venous thromboembolism among patients with cancer: the American Society of Clinical Oncology Guidelines. Thromb Res 125(Suppl 2):S120–127CrossRefPubMed
15.
Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187–3205CrossRefPubMed
16.
NCCN Clinical Practice Guidelines in Oncology. Myeloid Growth Factors. Version 2.2014. NCCN.org
17.
Sorgel F, Lerch H, Lauber T (2010) Physicochemical and biologic comparability of a biosimilar granulocyte colony-stimulating factor with its reference product. BioDrugs 24:347–357CrossRefPubMed
18.
Gascon P, Fuhr U, Sorgel F, Kinzig-Schippers M, Makhson A, Balser S, Einmahl S, Muenzberg M (2010) Development of a new G-CSF product based on biosimilarity assessment. Ann Oncol 21:1419–1429CrossRefPubMed
19.
Verpoort K, Möhler TM (2012) A non-interventional study of biosimilar granulocyte colony-stimulating factor as prophylaxis for chemotherapy-induced neutropenia in a community oncology centre. Ther Adv Med Oncol 4:289–293CrossRefPubMedPubMedCentral
20.
Salesi N, Di Cocco B, Colonna M, Veltri E (2012) Biosimilar medicines in oncology: single-center experience with biosimilar G-CSF. Future Oncol 8:625–630CrossRefPubMed
21.
Sandoz. Zarzio® (filgrastim). Summary of product characteristics.
22.
Gascon P, Tesch H, Verpoort K, Rosati MS, Salesi N, Agrawal S, Wilking N, Barker H, Muenzberg M, Turner M (2013) Clinical experience with Zarzio(R) in Europe: what have we learned? Support Care Cancer 21:2925–2932CrossRefPubMedPubMedCentral
23.
Tesch H, Indorf M, Rezvani M, Turner M Hexafil: A non-interventional study of the treatment of chemotherapy-induced neutropenia with Zarzio®/filgrastim Hexal®. Annual conference of the Deutsche Gesellschaft für Hämatologie und Onkologie (DGHO) Association, 2010 [Poster]
Metadata
Title
Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study
Authors
Sophie Nahon
Mansour Rastkhah
Meher Ben Abdelghani
Ravaka-Fatoma Soumoudronga
Isabelle Gasnereau
Jean-Luc Labourey
Publication date
01-05-2016
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 5/2016
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-015-2986-0

Other articles of this Issue 5/2016

Supportive Care in Cancer 5/2016 Go to the issue

Original Article

Efficacy of venlafaxine for the relief of taxane and oxaliplatin-induced acute neurotoxicity: a single-center retrospective case–control study

Original Article

Characteristics and outcomes of patients with advanced cancer evaluated by a palliative care team at an emergency center. A retrospective study

Original Article

Effects of a physical therapy program combined with manual lymphatic drainage on shoulder function, quality of life, lymphedema incidence, and pain in breast cancer patients with axillary web syndrome following axillary dissection

Original Article

End-of-life decision-making of terminally ill cancer patients in a tertiary cancer center in Shanghai, China

Original Article

Family caregiving challenges in advanced colorectal cancer: patient and caregiver perspectives

Original Article

Thyroid cancer survivors’ perceptions of survivorship care follow-up options: a cross-sectional, mixed-methods survey
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits